Exposure to US Cancer Drugs With Lack of Confirmed Benefit After US Food and Drug Administration Accelerated Approval

Ravi B Parikh; Rebecca A Hubbard; Erkuan Wang; Trevor J Royce; Aaron B Cohen; Amy S Clark; Ronac Mamtani

doi:10.1001/jamaoncol.2022.7770

Exposure to US Cancer Drugs With Lack of Confirmed Benefit After US Food and Drug Administration Accelerated Approval

JAMA Oncol. 2023 Apr 1;9(4):567-569. doi: 10.1001/jamaoncol.2022.7770.

Authors

Ravi B Parikh¹, Rebecca A Hubbard¹, Erkuan Wang¹, Trevor J Royce², Aaron B Cohen², Amy S Clark¹, Ronac Mamtani¹

Affiliations

¹ Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
² Flatiron Health, New York, New York.

No abstract available

Plain language summary

This cross-sectional study evaluates patient exposure to oncology drugs withdrawn from the US Food and Drug Administration (FDA) Accelerated Approval program.

MeSH terms

Antineoplastic Agents* / adverse effects
Drug Approval
Humans
Neoplasms* / drug therapy
United States
United States Food and Drug Administration

Substances

Antineoplastic Agents

Plain language summary

MeSH terms

Substances

Grants and funding